Organon, which is in the process of spinning off from Merck & Company, will acquire for $240 million Alydia Health, which makes medical devices to prevent the effects caused by postpartum bleeding. The deal is expected to close after the Organon spinoff is completed, which is expected to occur in Q2 2021.